July 9, 2019 / 8:41 PM / 2 months ago

BRIEF-Mirati Announces Clinical Collaboration To Evaluate Mrtx849 In Combination With Shp2 Inhibitor Tno155

July 9 (Reuters) - Mirati Therapeutics Inc:

* MIRATI ANNOUNCES CLINICAL COLLABORATION TO EVALUATE MRTX849 IN COMBINATION WITH SHP2 INHIBITOR TNO155

* MIRATI THERAPEUTICS INC - NOVARTIS WILL PROVIDE TNO155 AT NO COST.

* MIRATI THERAPEUTICS INC - UNDER TERMS OF NON-EXCLUSIVE COLLABORATION, MIRATI WILL SPONSOR TRIAL

* MIRATI THERAPEUTICS INC - NOVARTIS AND MIRATI WILL JOINTLY OVERSEE AND SHARE COSTS OF CLINICAL DEVELOPMENT ACTIVITIES FOR COMBINED THERAPY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below